Pre-clinical data have suggested that FLT3‐ITD mutation in AML may produce intrinsic/primary resistance to venetoclax by enhancing the expression of anti-apoptotic BCL-2 relatives such as BCL‐XL and MCL‐1 (Figure 1) (54, 55). This evidence concerns the gene BCL2 and acute myeloid leukemia.